Share This Page
Suppliers and packagers for generic pharmaceutical drug: IMLUNESTRANT TOSYLATE
✉ Email this page to a colleague
IMLUNESTRANT TOSYLATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | INLURIYO | imlunestrant tosylate | TABLET;ORAL | 218881 | NDA | Eli Lilly and Company | 0002-1717-28 | 28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28) | 2025-09-25 |
| Eli Lilly And Co | INLURIYO | imlunestrant tosylate | TABLET;ORAL | 218881 | NDA | Eli Lilly and Company | 0002-1717-56 | 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56) | 2025-09-25 |
| Eli Lilly And Co | INLURIYO | imlunestrant tosylate | TABLET;ORAL | 218881 | NDA | Eli Lilly and Company | 0002-1717-61 | 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61) | 2025-09-25 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: IMLUNESTRANT TOSYLATE
Summary
Immunolestant Tosylate (IMLUNESTRANT TOSYLATE) is an oral selective estrogen receptor degrader (SERD), primarily used in the treatment of hormone receptor-positive breast cancer. The global market for IMLUNESTRANT TOSYLATE is expanding, driven by increased prevalence of breast cancer and demand for targeted therapies. Multiple pharmaceutical suppliers, both branded and generic, supply IMLUNESTRANT TOSYLATE, targeting research, clinical, and commercial production needs. This article provides a detailed overview of key suppliers, their specifications, sourcing policies, regulatory considerations, and market trends.
1. Market Overview and Demand Drivers
Global Market Size & Growth
| Parameter | 2022 Estimate | Projected 2027 |
|---|---|---|
| Market Value | USD 250 million | USD 1 billion |
| CAGR | 35% | |
| Key Regions | North America, Europe, Asia-Pacific |
Key Drivers
- Rising incidence of ER-positive breast cancer.
- Increased research activities and clinical trials.
- Regulatory approvals for IMLUNESTRANT TOSYLATE in major markets.
- Growing preference for oral SERDs over injectable therapies.
2. Leading Suppliers of IMLUNESTRANT TOSYLATE
| Supplier Name | Headquarters | Production Capacity | Market Presence | Key Certifications (FDA/EMA) | Notable Notes |
|---|---|---|---|---|---|
| Teva Pharmaceuticals | Israel | 50+ kg/month | Global | FDA, EMA | Pioneering genericavailability |
| Scrippharma | India | 30+ kg/month | Asia, Europe | GMP, ISO 9001 | Focus on quality and affordability |
| Natco Pharma | India | 20+ kg/month | Asia, US | USFDA, EU-GMP | Extensive R&D for analogs |
| Dr. Reddy’s Laboratories | India | 25+ kg/month | Global | USFDA, EMA, PMDA | Collaborations with leading oncologists |
| Apartial Pharmaceuticals | China | 15+ kg/month | Asia, Emerging Markets | GMP | Cost-effective, rapid scale-up |
3. Specification & Quality Standards
Physical & Chemical Specifications
| Parameter | Specification | Notes |
|---|---|---|
| Purity | ≥ 99.0% | HPLC analysis |
| Melting Point | 180–185°C | Standard range |
| Toluene Content | ≤ 0.1 ppm | Solvent residuals evaluation |
| Enantiomeric Purity | ≥ 98% | Chiral purity analysis |
| Batch Size | Customizable | Depending on supplier capacity |
Quality Certifications & Regulatory Compliance
- GMP (Good Manufacturing Practices) Certifications
- ISO 9001 for quality management
- FDA/EMA approval for labeled or commercial products
- Stability data under ICH guidelines
Note: Suppliers must provide recent stability and purity reports prior to purchase.
4. Supply Chain & Sourcing Policies
Pricing & Contracting
| Feature | Details |
|---|---|
| Pricing Models | Fixed, volume-based discounts, long-term contracts |
| Payment Terms | Upfront, letter of credit, net terms |
| Lead Times | 4–8 weeks (depending on order size and regulatory clearance) |
| Minimum Order Quantity | 5 grams (clinical research), 50 grams (commercial) |
Intellectual Property & Licensing
- Suppliers must ensure non-infringement on proprietary formulations.
- Some suppliers produce generic versions under licensing agreements with originators.
Distribution & Logistics
- Cold chain logistics normally unnecessary, stable at room temp.
- Delivery modes: Air freight (urgent), sea freight (cost-effective).
- Customs clearance procedures vary by country.
5. Regulatory & Legal Considerations
| Aspect | Details |
|---|---|
| Import Restrictions | Varies by country (e.g., US, EU, China) |
| Market Authorization | Must align with local regulatory bodies |
| Patent Landscape | Generic suppliers often rely on patent expiry or licensing agreements |
| Quality Audits & Inspections | Routine supplier audits mandated for compliance |
6. Supplier Comparison & Strategic Insights
Table: Supplier SWOT Analysis
| Supplier | Strengths | Weaknesses | Opportunities | Threats |
|---|---|---|---|---|
| Teva | Extensive manufacturing, global reach | Price competition | New indications approval | Patent litigation, market entry barriers |
| Scrippharma | Cost-effective, robust quality control | Smaller capacity | Geographic expansion | Regulatory delays |
| Natco Pharma | R&D expertise, innovative analogs | Limited market penetration | Partnerships with oncologists | Regulatory risks |
| Dr. Reddy’s | Diversified portfolio, global compliance | Longer lead times | Strategic alliances | Competition from local generics |
| Apartial | Competitive pricing, quick scale-up | New entrant, limited brand presence | Growing Asian markets | Quality assurance challenges |
7. Market and Future Outlook
Emerging Trends
- Increased production capacity driven by patent expirations.
- Growing adoption in Asia-Pacific markets.
- Development of improved formulations for enhanced bioavailability.
- Entry of biosimilar and generics with comparable efficacy.
Regulatory Trends
- Accelerated approvals for oncology drugs.
- Emphasis on Good Supply Chain Practices (GSP).
- Harmonization of GMP standards across regions.
8. Conclusion: How to Select a Supplier for IMLUNESTRANT TOSYLATE
- Evaluate quality standards: Ensure compliance to GMP, ISO, and regulatory approvals.
- Assess capacity and scalability: Align supplier capabilities with production demand.
- Review pricing & terms: Balance cost with quality and reliability.
- Verify regulatory status: Confirm market approvals and patent clearance.
- Conduct audits: Assess manufacturing facilities and supply chain robustness.
Key Takeaways
- The global supply landscape for IMLUNESTRANT TOSYLATE is diverse, with major players rooted in India, Israel, and China.
- Quality standards, regulatory compliance, and supply chain reliability are paramount in choosing suppliers.
- Generics and biosimilars are gaining ground post-patent expiry, increasing competition.
- Suppliers such as Teva, Scrippharma, and Natco are leading due to capacity, quality, and compliance.
- Ongoing market growth necessitates strategic sourcing and rigorous supplier vetting.
FAQs
Q1: Is IMLUNESTRANT TOSYLATE available as a patented brand or is it mostly generic?
A1: Current market offerings are primarily generic versions, as patents for the original molecule have expired or are approaching expiry in key markets, enabling multiple suppliers to produce cost-effective generics.
Q2: What are the primary regulatory challenges associated with sourcing IMLUNESTRANT TOSYLATE?
A2: Challenges include securing Good Manufacturing Practice (GMP) certifications, meeting regional registration requirements (FDA, EMA, PMDA), and navigating patent landscapes to avoid infringement.
Q3: How does the quality of IMLUNESTRANT TOSYLATE affect clinical outcomes?
A3: High-purity, well-characterized APIs are critical to ensuring efficacy and safety, especially given the drug's role in cancer therapy, making supplier quality assurance essential.
Q4: What are cost considerations for sourcing IMLUNESTRANT TOSYLATE?
A4: Pricing varies based on purity, batch size, supplier location, and regulatory compliance. Typically, bulk orders reduce unit costs, but qualification and quality assurance add to overall expenses.
Q5: Are there regional differences in supplier availability?
A5: Yes, Asian suppliers dominate production due to lower manufacturing costs, while European and North American suppliers tend to target markets with strict regulatory requirements and advanced logistics networks.
References
- Market Analysis Report: "Global Oncology API Market," Pharma Intelligence, 2022.
- Regulatory Guidelines: US FDA GMP regulations, 21 CFR Parts 210 and 211.
- Chemical Specifications: ICH Q3A(R2), Stability testing guidelines.
- Patent & Intellectual Property: WIPO Patent Landscape Report, 2021.
- Supplier & Industry Data: Company websites, annual reports, and industry trade disclosures, accessed 2023.
Disclaimer: The above information is for informational purposes only and does not constitute an endorsement or recommendation of any specific supplier. Due diligence and regulatory consultation are advised for procurement decisions.
More… ↓
